Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

Lisa Bodei, Marta Cremonesi, Chiara Grana, Paola Rocca, Mirco Bartolomei, Marco Chinol, Giovanni Paganelli

Research output: Contribution to journalArticlepeer-review


Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [ 90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

Original languageEnglish
Pages (from-to)1038-1046
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number7
Publication statusPublished - Jul 2004


  • Neuroendocrine tumours
  • Receptor radionuclide therapy
  • Somatostatin receptors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology


Dive into the research topics of 'Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this